PALBOCICLIB REAL WORLD DATA IN ADVANCED AND METASTATIC BREAST CANCER TREATED: A MULTICENTER EXPERIENCE IN LEBANON

被引：0
作者：
Nasr, Fadi [1 ,2 ,3 ]
Diab, Saada [1 ]
Al Ghoche, Ahmad [1 ]
Yehia, Intissar [1 ]
Nasr, Lewis [2 ]
机构：
[1] Balamand Univ Beirut, Dept Hematol Oncol, Mt Lebanon Univ Hosp, Beirut, Lebanon
[2] St Joseph Univ, Dept Hematol Oncol, Hotel Dieu France Univ Hosp, Fac Med, Beirut, Lebanon
[3] Univ St Esprit Kaslik, Notre Dame Secours Univ Hosp, Fac Med, Jounieh, Lebanon
来源：
BREAST | 2021年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO61
引用
收藏
页码：S48 / S48
页数：1
相关论文
共 50 条
  • [31] Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia
    Sun, James
    Zhong, Xiaojun
    Ma, Junjie
    Sun, Weihong
    Han, Hyo S.
    Soliman, Hatem H.
    Loftus, Loretta S.
    Costa, Ricardo L. B.
    Armaghani, Avan J.
    Soyano-Muller, Aixa E.
    Czerniecki, Brian J.
    Lee, M. Catherine
    Kiluk, John, V
    Khakpour, Nazanin
    Hoover, Susan J.
    Laronga, Christine
    Khong, Hung T.
    CANCER MEDICINE, 2021, 10 (21): : 7665 - 7672
  • [32] Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval
    Kish, J. K.
    Ward, M. A.
    Garofalo, D.
    Ahmed, H. V.
    Mcroy, L.
    Laney, J.
    Zanotti, G.
    Braverman, J.
    Yu, H.
    Feinberg, B. A.
    BREAST CANCER RESEARCH, 2018, 20
  • [33] Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval
    J. K. Kish
    M. A. Ward
    D. Garofalo
    H. V. Ahmed
    L. McRoy
    J. Laney
    G. Zanotti
    J. Braverman
    H. Yu
    B. A. Feinberg
    Breast Cancer Research, 20
  • [34] Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review
    Brain, Etienne
    Chen, Connie
    Simon, Sofia
    Pasupuleti, Vinay
    Pfitzer, Kathleen Vieira
    Gelmon, Karen A.
    TARGETED ONCOLOGY, 2024, 19 (03) : 303 - 320
  • [35] Everolimus in heavily pre-treated metastatic breast cancer (MBC): Is real (developing) world experience different?
    Bajpai, J.
    Ramaswamy, A.
    Ghosh, J.
    Gulia, S.
    Gupta, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S292 - S292
  • [36] Initial real-world experience with ribociclib in advanced breast cancer
    Nawaz, Azhar
    Zekri, Jamal
    Rasool, Haleem
    Ibrahim, Refaei
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2025,
  • [37] Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced/Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy
    Bui, Tam Binh V.
    Burgers, Desiree M. T.
    Agterof, Mariette J.
    van de Garde, Ewoudt M. W.
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2019, 13
  • [38] Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study
    Mycock, Katie
    Zhan, Lin
    Hart, Kieran
    Taylor-Stokes, Gavin
    Milligan, Gary
    Atkinson, Christian
    Mitra, Debanjali
    FUTURE ONCOLOGY, 2021, 18 (03) : 349 - 362
  • [39] Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer
    Acedo, Rocio Diaz
    Banqueri, Mercedes Galvan
    Criado, Silvia Artacho
    Parra, Eva Maria Fernandez
    Galan, Rocio Jimenez
    Sanchez, Ana Isabel Gago
    Pozo, Juan Francisco Marin
    Bautista, Maria Jose Martinez
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (02) : 382 - 389
  • [40] Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer
    Rocío Díaz Acedo
    Mercedes Galvan Banqueri
    Silvia Artacho Criado
    Eva María Fernández Parra
    Rocío Jiménez Galán
    Ana Isabel Gago Sánchez
    Juan Francisco Marín Pozo
    María José Martínez Bautista
    International Journal of Clinical Pharmacy, 2024, 46 : 382 - 389
12345